Voyager Therapeutics, Inc. (VYGR) stock
VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3040% below fair value
$1.73+0.03 (+1.76%)
Close on Nov 13, 2026Market cap $106.60MP/E –Yield –
Voyager Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Voyager Therapeutics's enterprise value was -$40.96M on Nov 11, 2026, against -$2.08M a year earlier. Over the last 5 years it ranged from -$147.41M to $232.03M, with a median of $40.40M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$40.96M | – |
| 2025 | Dec 31, 2025 | -$10.95M | – |
| 2024 | Dec 31, 2024 | -$36.15M | -130.7% |
| 2023 | Dec 29, 2023 | $117.69M | +13.9% |
| 2022 | Dec 30, 2022 | $103.37M | – |
| 2021 | Dec 31, 2021 | -$19.11M | -128.8% |
| 2020 | Dec 31, 2020 | $66.43M | -67.8% |
| 2019 | Dec 31, 2019 | $206.35M | +66.3% |
| 2018 | Dec 31, 2018 | $124.11M | -60.0% |
| 2017 | Dec 29, 2017 | $310.16M | +133.8% |
| 2016 | Dec 30, 2016 | $132.64M | – |
| 2015 | Dec 31, 2015 | -$77.67M | – |
See a number that looks wrong?